Pharmacogenomics: What is next?

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  di Iulio, Julia ^a   Rotger, Margalida ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

GWAS; Next generation sequencing; Pharmacogenomics

Indexed keywords

ABACAVIR; ACYLTRANSFERASE; CLOPIDOGREL; DNA; FLUCLOXACILLIN; ISONIAZID; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PEGINTERFERON ALPHA; PROTEOME; RIBAVIRIN; RITONAVIR; RNA; SIMVASTATIN; TRANSCRIPTOME; WARFARIN;

ALTERNATIVE RNA SPLICING; ARTICLE; CYP2C19 GENE; DISEASE PREDISPOSITION; DNA SEQUENCE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EXOME; GENE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HEPATITIS C; HIGH THROUGHPUT SEQUENCING; HLA B5701 GENE; HOMOZYGOSITY; HUMAN; HUMAN GENOME PROJECT; IL28B GENE; MASS SPECTROMETRY; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; REPRODUCIBILITY; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 5 GENE; TOXIC HEPATITIS;

EID: 84863625500     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00086     Document Type: Article

References (33)

1. Cha, P. C., Mushiroda, T., Takahashi, A., Kubo, M., Minami, S., Kamatani, N., and Nakamura, Y. (2010). Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744.
2. Chou, F. C., Tzeng, S. J., and Huang, J. D. (2001). Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. 29, 1205-1209.
3. Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., Veenstra, D. L., Rettie, A. E., and Rieder, M. J. (2008). A genome- wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027.
4. Daly, A. K. (2010). Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11, 241-246.
5. *5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819.
6. di Iulio, J., Ciuffi, A., Fitzmaurice, K., Kelleher, D., Rotger, M., Fellay, J., Martinez, R., Pulit, S., Furrer, H., Gunthard, H. F., Battegay, M., Bernasconi, E., Schmid, P., Hirschel, B., Barnes, E., Klenerman, P., Telenti, A., and Rauch, A. (2011). Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 53, 1446-1454.
7. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., Sulkowski, M., Mchutchison, J. G., and Goldstein, D. B. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401.
8. [1000] Genomes Project Consortium. (2010). A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073.
9. Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., and Manolio, T. A. (2009). Potential etiologic and functional implications of genome- wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U.S.A. 106, 9362-9367.
10. International HapMap Consortium. (2003). The international HapMap project. Nature 426, 789-796.
11. International HapMap Consortium. (2005). A haplotype map of the human genome. Nature 437, 1299-1320.
12. Kinzig-Schippers, M., Tomalik-Scharte, D., Jetter, A., Scheidel, B., Jakob, V., Rodamer, M., Cascorbi, I., Doroshyenko, O., Sorgel, F., and Fuhr, U. (2005). Should we use N -acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49, 1733-1738.
13. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkatara- manan, R., Strom, S., Thummel, K., Boguski, M. S., and Schuetz, E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
14. Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., Schwab, M., and Zanger, U. M. (2004). Multi- ple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311, 34-43.
15. Legrain, P., Aebersold, R., Archakov, A., Bairoch, A., Bala, K., Beretta, L., Bergeron, J., Borchers, C. H., Corthals, G. L., Costello, C. E., Deutsch, E. W., Domon, B., Han- cock, W., He, F., Hochstrasser, D., Marko-Varga, G., Salekdeh, G. H., Sechi, S., Snyder, M., Srivastava, S., Uhlen, M., Wu, C. H., Yamamoto, T., Paik,Y. K., and Omenn, G. S. (2011). The human proteome project: cur- rent state and future direction. Mol. Cell Proteomics 10, M111 009993.
16. Leschziner, G. D., Andrew, T., Pirmo- hamed, M., and Johnson, M. R. (2007). ABCB1 genotype and PGP expression, function and therapeu- tic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7, 154-179.
17. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., and Collins, R. (2008). SLCO1B1 vari- ants and statin-induced myopathy - a genomewide study. N.Engl.J.Med. 359, 789-799.
18. Lubomirov, R., di Iulio, J., Fayet, A., Colombo, S., Martinez, R., Mar- zolini, C., Furrer, H., Vernazza, P., Calmy, A., Cavassini, M., Lederger- ber, B., Rentsch, K., Descombes, P., Buclin, T., Decosterd, L. A., Csajka, C., and Telenti, A. (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the anti- retroviral agent lopinavir coformu- lated with ritonavir. Pharmacogenet. Genomics 20, 217-230.
19. *5701 screening for hypersensitivity to abacavir. N.Engl.J.Med.358, 568-579.
20. Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter,D. J.,Mccarthy,M. I.,Ramos, E. M., Cardon, L. R., Chakravarti, A., Cho, J. H., Guttmacher, A. E., Kong, A., Kruglyak, L., Mardis, E., Rotimi, C. N., Slatkin, M., Valle, D., Whit- temore, A. S., Boehnke, M., Clark, A. G., Eichler, E. E., Gibson, G., Haines, J. L., Mackay, T. F., Mccar- roll, S. A., and Visscher, P. M. (2009). Finding the missing heritability of complex diseases. Nature 461, 747-753.
21. Marez, D.,Sabbagh, N., Legrand, M., Lo- Guidice, J. M., Boone, P.,and Broly, F. (1995). A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabo- lizer phenotype. Pharmacogenetics 5, 305-311.
22. Menard, V., Eap, O., Roberge, J., Harvey, M., Levesque, E., and Guillemette, C. (2011). Transcriptional diver- sity at the UGT2B7 locus is dic- tated by extensive pre-mRNA splic- ing mechanisms that give rise to multiple mRNA splice vari- ants. Pharmacogenet. Genomics 21, 631-641.
23. Nebert, D. W., Zhang, G., and Vesell, E. S. (2008). From human genet- ics and genomics to pharmaco- genetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40, 187-224.
24. Nilsson, T., Mann, M., Aebersold, R., Yates, J. R. III., Bairoch, A., and Berg-eron, J. J. (2010). Mass spectrome- try in high-throughput proteomics: ready for the big time. Nat. Methods 7, 681-685.
25. Ozsolak, F., and Milos, P. M. (2011). RNA sequencing: advances, chal- lenges and opportunities. Nat. Rev. Genet. 12, 87-98.
26. Pitarque, M., Von Richter, O., Oke, B., Berkkan, H., Oscarson, M., and Ingelman-Sundberg, M. (2001). Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284, 455-460.
27. Rauch, A., Kutalik, Z., Descombes, P., Cai, T., di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., Colombo, S., Cerny, A., Dufour, J. F., Furrer, H., Gunthard, H. F., Heim, M., Hirschel, B., Malinverni, R., Moradpour, D., Mullhaupt, B., Witteck, A., Beckmann, J. S., Berg, T., Bergmann, S., Negro, F., Telenti, A., and Bochud, P. Y. (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide associa- tion study. Gastroenterology 138, 1338-1345.
28. Shuldiner, A. R., O'connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q., Pollin, T. I., Post, W., Parsa, A., Mitchell, B. D., Faraday, N., Her- zog, W., and Gurbel, P. A. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857.
29. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli,V., Muller, T., Bahlo, M. Stew- art, G. J., Booth, D. R., and George, J. (2009). IL28B is asso- ciated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104.
30. Takeuchi, F., Mcginnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., Mclaren, W., Holm, L., Lindh, J., Rane, A., Wadelius, M., and Deloukas, P. (2009). A genome-wide associ- ation study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433. doi: 10.1371/journal.pgen. 1000433
31. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., Ito, Y., Mita, E., Tanaka, E., Mochida, S., Murawaki, Y., Honda, M., Sakai, A., Hiasa, Y., Nishiguchi, S., Koike, A., Sakaida, I., Imamura, M., Ito, K., Yano, K., Masaki, N., Sugauchi, F., Izumi, N., Tokunaga, K., and Mizokami, M. (2009). Genome- wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109.
32. Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O'huigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., Goedert, J. J., Kirk, G. D., Donfield, S. M., Rosen, H. R., Tobler, L. H., Busch, M. P., Mchutchison, J. G., Goldstein, D. B., and Carrington, M. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801.
33. Wang, L., Mcleod, H. L., and Wein- shilboum, R. M. (2011). Genomics and drug response. N.Engl.J.Med. 364, 1144-1153.